Wolfe Research initiated coverage on Viking Therapeutics
$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2026 | Peer Perform | Wolfe Research | |
| 10/29/2025 | $106.00 | Buy | Canaccord Genuity |
| 4/29/2025 | $104.00 | Overweight | Cantor Fitzgerald |
| 4/8/2025 | $30.00 | Neutral | Goldman |
| 2/13/2025 | $102.00 | Sector Outperform | Scotiabank |
| 2/7/2025 | $38.00 | Neutral | Citigroup |
| 12/2/2024 | Overweight | Piper Sandler | |
| 11/22/2024 | $109.00 | Buy | B. Riley Securities |
10-K - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform
Canaccord Genuity initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $106.00
Cantor Fitzgerald initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $104.00
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4/A - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on ScheduleVK2735 Phase 1 Maintenance Dosing Study UnderwayAdditional Phase 2a VENTURE Study Data to be Presented at ObesityWeek in NovemberStrong Quarter-End Cash Position of $715 MillionSAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2025, and provided an update on its clinical pipeline and other corporate deve
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)